Vol. 3, Issue 5

June 2026

Your Quarterly Gateway to Medical Device Trends, Talent, and Transformation

Pulse of Innovation: How Medical Device Leaders Are Navigating Consolidation, Emerging Technologies, and Industry Transformation

In this issue, we explore how the medical device industry is entering a new era shaped by consolidation, technological innovation, and evolving regulatory expectations. Today's market leaders are navigating a landscape where success increasingly depends on integrating acquisitions effectively, accelerating innovation responsibly, and building leadership teams capable of managing complexity at scale. As the industry evolves, medical device companies are redefining what it means to compete, grow, and lead.

Across the industry, transformative transactions such as Danaher's $9.9 billion acquisition of Masimo and Hologic's $18.3 billion go-private are reshaping competitive dynamics and strategic priorities. At the same time, advances in AI-enabled diagnostics, software-driven devices, and connected care platforms are increasing demand for leaders who can bridge clinical innovation, regulatory compliance, and commercial execution. The organizations creating the greatest long-term value are those that combine strategic vision with operational discipline.

The executives stepping into leadership roles today inherit both extraordinary opportunity and heightened complexity. Whether leading post-acquisition integration, navigating evolving FDA oversight, or scaling next-generation technologies, success increasingly depends on leaders who can operate at the intersection of innovation, execution, and sustainable growth.

Medtech M&A deal value in 2025 — the highest total in over a decade, per PwC

Global medical device market size in 2026, projected to reach $1T+ by 2034

Medtech M&A deals in Q1 2026 alone, totaling $26.6B in value, per J.P. Morgan

INDUSTRY SPOTLIGHT

Medtronic Files to Expand Hugo Surgical Robot Into General Surgery and Gynecology — and Sends a Signal to Every Device Company Watching the Robotics Race

GALWAY, Ireland — Medtronic plc reported fourth quarter and full year fiscal 2026 results on June 3, 2026, delivering its highest annual top-line growth in a decade. Full year revenue reached $36.4 billion, up 8.4% as reported and 5.8% organic, with Q4 revenue of $9.8 billion surpassing guidance by 90 basis points. Cardiac Ablation Solutions led all segments with 78% global growth — including 124% U.S. growth — as the Affera pulsed field ablation platform continued to gain share. The Medical Surgical portfolio grew 5.1% organically, led by double-digit gains in Acute Care & Monitoring.

Alongside the financial results, Medtronic submitted 510(k) filings to expand its Hugo robotic-assisted surgery (RAS) system into general surgery and gynecologic specialties in the U.S., and secured CE Mark for the Stealth AXiS surgical system in spine and cranial indications across Europe. The company also announced its intent to acquire SPR Therapeutics to expand chronic pain management capabilities, and raised its quarterly dividend to $0.72 per share — marking the 49th consecutive year of dividend increases. CEO Geoff Martha cited the results as "the compounding impact of deliberate choices" made to sharpen execution and invest in high-growth platforms including Affera, Symplicity, Hugo, and Stealth AXiS.

Read the Full Announcement

PEOPLE ON THE MOVE

5 Biggest Moves In The Last 90 Days

Johan Folkunger joined Boule Diagnostics as CEO

Boule Diagnostics has appointed Johan Folkunger as CEO, effective June 22, 2026, succeeding Interim CEO Simonetta Tumbiolo. Folkunger brings extensive international leadership experience in healthcare and medtech, including CEO roles at DNV Imatis, SpectraCure, Philips Sweden, and executive leadership at MedCap. The Board cited his strong strategic and operational background as key to leading Boule’s next phase of growth.

View Johan's Profile

Hologic announced today that it named a seasoned medtech veteran as its CEO after closing its go-private acquisition.

Hologic completed its $18.3 billion take-private acquisition by Blackstone and TPG and simultaneously appointed former Baxter CEO José (Joe) Almeida as chief executive officer, succeeding longtime CEO Steve MacMillan upon the deal's close. Almeida's appointment underscores a broader trend across medtech and healthcare companies of pairing major portfolio transformations with experienced operators known for driving strategic focus, operational discipline, and growth. During his tenure at Baxter, Almeida led significant portfolio reshaping initiatives, including major acquisitions and divestitures designed to concentrate resources on higher-growth segments. His appointment at Hologic signals an emphasis on accelerating innovation, strengthening market leadership in women's health, and executing long-term growth strategies under private ownership.

Learn More

Teleflex Appoints Jason Weidman as President and CEO

Teleflex appointed longtime Medtronic executive Jason Weidman as President and CEO, effective June 2026, as the company advances a significant portfolio transformation following multiple divestitures. Weidman, who previously led Medtronic's multi-billion-dollar Coronary & Renal Denervation and Aortic, Peripheral & Venous businesses, was selected to guide Teleflex's next phase of growth focused on interventional, critical care, and high-acuity hospital markets. The appointment reflects a broader trend across the medtech sector of bringing in experienced operating leaders to drive focused growth strategies, accelerate innovation, and unlock value following major portfolio restructuring efforts.

View Jason's Profile

Edwards Lifesciences Announces Appointment of CFO

Edwards Lifesciences appointed Theodora (“Doretta”) Mistras as Chief Financial Officer, effective May 2026, bringing in a seasoned healthcare finance executive from Viatris and a former healthcare investment banker at Citigroup and Goldman Sachs. Mistras succeeds longtime CFO Scott Ullem as Edwards continues executing its differentiated structural heart strategy and investing in innovation-driven growth. The appointment reflects a broader trend across medtech of strengthening executive leadership teams with experienced financial operators who can support strategic capital allocation, M&A evaluation, investor engagement, and long-term value creation as companies navigate increasingly complex growth and innovation cycles.

View Doretta's Profile

Integra reappoints Stuart Essig as CEO

Integra LifeSciences reappointed longtime board chairman and former CEO Stuart Essig as President and Chief Executive Officer, bringing back a proven company veteran to lead the next phase of operational execution and commercial growth. Essig, who previously served as CEO from 1997 to 2012, was tasked with accelerating progress across quality, compliance, operational resilience, and customer-focused transformation initiatives, while the company also elevated commercial leadership through the creation of a new Chief Commercial Officer role. The move reflects a broader trend across medtech of boards turning to experienced insiders with deep institutional knowledge to drive execution, strengthen commercial performance, and navigate complex operational transformations during periods of strategic transition.

View Stuart's Profile

Complete List of C-Level Promotions and Hires in the

Last 90 Days

MEDICAL DEVICE INSIGHTS

Danaher Completes $9.9B Acquisition of Masimo — Patient Monitoring Is Being Rebuilt Around a New Strategic Owner

Danaher Corporation completed its $9.9 billion acquisition of Masimo Corporation on June 10, 2026, making Masimo a wholly-owned subsidiary and standalone operating company within Danaher's Diagnostics segment. Masimo common stock ceased trading on Nasdaq at close. The deal — announced February 17, 2026 at $180 per share — brings Masimo's pulse oximetry, AI-enabled continuous monitoring, and acute care sensor technology into one of medtech's most operationally disciplined parent platforms. Danaher CEO Rainer Blair cited "clear opportunities to enhance Masimo's performance through DBS and our global scale." For device talent leaders, the Danaher Business System (DBS) integration playbook historically drives significant commercial, operational, and quality leadership restructuring in the 12–18 months post-close — and the monitoring segment is now watching closely.

American Cancer Society Adds Guardant Health's Shield Blood Test to CRC Screening Guidelines — Liquid Biopsy Reaches a New Milestone

The American Cancer Society released updated colorectal cancer screening guidelines on May 27, 2026, adding Guardant Health's FDA-approved Shield™ blood test as a recommended option for patients who decline or have not completed stool-based or visual screening. Shield is now the first and only FDA-approved blood test included in both ACS and NCCN guidelines. More than 50 million Americans are eligible for colorectal cancer screening but remain unscreened — a gap the guideline update directly targets. In real-world experience with approximately 200,000 patients tested, Shield demonstrated a 93% screening adherence rate, outperforming traditional options in patient completion. For device and diagnostics talent leaders, the ACS inclusion marks a commercial inflection point: liquid biopsy companies are now competing for market access leaders, payer relations executives, and field oncology specialists who can drive adoption at primary care scale.

Insulet Reveals Omnipod 6 and Fully Closed-Loop AID Data at ADA Scientific Sessions — Automated Insulin Delivery Enters Its Next Chapter

Insulet Corporation presented new clinical data supporting its Omnipod 6 automated insulin delivery (AID) system and its fully closed-loop technology at the American Diabetes Association's 86th Scientific Sessions in June 2026, demonstrating improved outcomes and reduced management burden for patients with Type 1 and Type 2 diabetes. The data arrives as Insulet, Medtronic's MiniMed spinoff, Dexcom, and Abbott compete aggressively in the AID space — each advancing distinct platform strategies for closed-loop insulin management. Abbott's CEO Robert Ford confirmed at the same conference that Libre Duo FDA clearance is expected in the second half of 2026. For device talent leaders, the ADA conference underscored that the diabetes technology segment is simultaneously the most innovation-dense and most competitive talent market in medical devices with demand intensifying for commercial, clinical education, and market access leaders across all four major platforms.

Spotlight Contributor

Bernard Layton

Talent Pulse Partners, Co-Founder

Bernard Layton is a seasoned executive search leader with more than 35 years of experience helping organizations align leadership talent with business-critical outcomes.

Throughout his career, Bernard has worked closely with boards, investors, and executive teams across highly regulated and complex industries, developing a deep understanding of how the right leadership expertise, at the right time, can materially impact performance, risk management, and growth. As healthcare and clinical service organizations faced increasing pressure to move faster without taking on long-term overhead, Bernard recognized a growing gap between traditional hiring models and the need for immediate, specialized leadership.

Over the past 15+ years, Bernard has been an innovator in talent intelligence and search infrastructure, designing proprietary CRM and data systems to support rigorous market mapping, long-term relationship management, and strategic talent deployment. This work culminated in KeyHires, a purpose-built platform that enables scalable access to deeply vetted leadership talent.

Talent Pulse Partners was created as a natural extension of this foundation—bringing fractional leadership to organizations that need senior clinical expertise without the cost, uncertainty, or extended timelines of full-time hiring.

Bernard’s work is grounded in the belief that exceptional outcomes, especially in healthcare, are driven by aligning the right expertise with the right mission, exactly when it is needed most.

More Information

Connect On LinkedIn

Questions? Ask Away!

;

— STAY AHEAD

Don't miss the next issue

Be at the forefront of the digital healthcare revolution. We provide you with insights on trends, talent management, and executive leadership — delivered with the depth your organization deserves.

This newsletter is sponsored by Talent Pulse Partners. At Talent Pulse Partners, we specialize in connecting organizations with exceptional executive talent that propels growth and success. In today's competitive landscape, the right leadership can make all the difference. Our team of experienced recruiters are dedicated to finding top-tier executives who possess the skills, vision, and expertise to drive your business forward.

Don't miss out on the opportunity to secure the top talent your company deserves. Contact Bernard Layton, leader of our digital health practice, at blayton@talentpp.com to learn more about how Talent Pulse Partners can help you find the exceptional leaders who will transform your organization.